A downsized core tablet containing nifedipine to be administered once a day which is obtained by, in the core comprising nifedipine and a hydrophilic gel-forming polymer, reducing the amount of the hydrophilic gel-forming polymer and adding a disintegration inhibitor thereto to thereby downsize the core without affecting the elution of nifedipine, and then compression-coating the core with a shell comprising nifedipine, a hydrophilic gel-forming polymer and a disintegration inhibitor. A combined...

An osmotic pharmaceutical release system comprises a hull which acts as a semi-permeable membrane, and a core containing the active ingredient (e.g. nifedipine), which is based on xanthan and a vinylpyrrolidone-vinyl acetate copolymer. An osmotic pharmaceutical release system comprises (1) a hull which is made from a material that is permeable to water but not to the active component, and which has one or more openings (2) a core containing 15-35 (preferably 20-30) wt. % of a dihydropyridine, 20...

A process is disclosed for preparing nifedipine by reacting 2-(2-nitrobenzylidene)acetic acid methyl ester and 3-aminocrotonic acid methyl ester, as well as the use of the thus prepared nifedipine for producing a medicament.

This invention provides a long-lasting release solid nifedipine preparation which exhibits clinically sufficient effect when administered once per day. A press coated tablet whose core and shell each contains nifedipine, the dissolution rate of nifedipine from said tablet being (a) in the dissolution test using a sinker according to method 2 of the dissolution test method as prescribed by the Pharmacopoeia of Japan, after 2 hours 10-40% after 4 hours 30-65% after 6 hours at least 55%, and (b) in...

A process is disclosed for preparing nifedipine by reacting 2-(2-nitrobenzylidene)acetic acid methyl ester and 3-aminocrotonic acid methyl ester, as well as the use of the thus prepared nifedipine for producing a medicament.

This invention provides a long-lasting release solid nifedipine preparation which exhibits clinically sufficient effect when administered once per day. ?Construction? A press coated tablet whose core and shell each contains nifedipine, the dissolution rate of nifedipine from said tablet being (a) in the dissolution test using a sinker according to method 2 of the dissolution test method as prescribed by the Pharmacopoeia of Japan, after 2 hours 10-40% after 4 hours 30-65% after 6 hours at least ...

A press coated tablet whose core and shell each contains nifedipine, the dissolution rate of nifedipine from said tablet being (a) in the dissolution test using a sinker according to method 2 of the dissolution test method as prescribed by the Pharmacopoeia of Japan, after 2 hours 10-40% after 4 hours 30-65% after 6 hours at least 55%, and (b) in the dissolution test according to the disintegration test method as prescribed by the Pharmacopoeia of Japan, after 3 hours 20-45% after 4 hours 30-65%...

The invention is directed to the provision of solid pharmaceutical compositions (and methods for their preparation) containing nifidipine crystals with a specific surface area of 1.0 to 4.0 m2/g., in admixture with a solid diluent. The said compositions overcome the deficiencies of prior art compositions containing nifidipine, which is known to have effect as a coronary vasodilator.